Pharmacokinetics of netilmicin during hemodialysis: comparison of four artificial kidneys.

The pharmacokinetics of netilmicin was studied in 11 patients with terminal renal impairment (Clcr less than 5 ml/min) during the course of a 4-h hemodialysis session, using four different kinds of dialyzer: Biospal 2400, Biospal 3000, Allegro HF, and Andante HF. All patients received a single dose of 2 mg netilmicin/kg body wt at the beginning of the dialysis session. The type of dialyzer influences the serum half-life, the dialysis clearance and the percentage of drug extracted during dialysis. A linear relationship was established between the drug fraction extracted by dialysis and the dialysis clearance of the antibiotic. During the hemodialysis sessions, the serum half-life of netilmicin decreased approximately 10-fold compared with the interdialysis periods.

Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis.

The pharmacokinetics of netilmicin was studied in 26 patients with varying degrees of renal impairment (11 were dialysis patients) in order to determine the influence of kidney function status on the disposition of the antibiotic. The serum level curves of netilmicin follows a two-compartment open kinetic model. Several relationships between pharmacokinetic parameters and renal function indicators are defined. A clinical useful correlation indicates that the half-life is approximately 3 times the serum creatinine concentration, and may be used for adjusting the netilmicin dosage in the treatment of patients with impaired renal function. During hemodialysis the serum half-life decreases approximately 10-fold compared with the interdialysis periods. The percentage of dose extracted by hemodialysis during a single 4 h session is 56.1 +/- 6.65%. The dialysis clearance is 87.28 +/- 28.8 ml/min.